About 37% of patients treated with Byetta and 57% patients treated with Bydureon tested positively for the presence of anti-drug antibodies [158]
Zhongguo Yi Xue Ke Xue Yuan Xue Bao
However, the coexistence of micro and macrovascular disease is associated with the highest cardiovascular risks which highlights the importance that pharmacological treatment of type 2 diabetes mellitus provides not only glycemic control, but also cardiovascular safety
In simple terms, Mounjaro provides all the insulin release, appetite regulation and blood sugar control benefits of a GLP-1 medication, but its additional targeting of GIP receptors enhances these effects
Despite the CV benefits of some GLP-1 RAs [34,35,36,37,38], there was no difference in the prescribing rates of GLP-1 RAs between people with and without CV disease history [30]